2017 Full year and fourth quarter
We announced our full year and fourth quarter 2017 results on Wednesday 7 February.
2010 Third Quarter - released 21 October 2010
Andrew Witty, CEO, discusses our third quarter results 2010
- Q3 EPS before major restructuring of 28.2p
- Q3 dividend up 7% to 16p
2010 Second Quarter - released 21 July 2010
Andrew Witty, CEO, discusses our second quarter results 2010.
- Q2 EPS before major restructuring 2.6p (29.3p excluding pre-announced legal charge)
- Q2 dividend increased 7% to 15p
2010 First Quarter - released 28 April 2010
Andrew Witty, CEO, discusses our first quarter results 2010.
- Q1 sales £7.4bn up 13% CER
- Underlying sales (excluding pandemic products) up 4% CER
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III